Essential Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Essential Partners’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$779	Sell	633 -1,437	-69%	-$2.29K	﹤0.01%	2272
2026 Q2	$4.41K	Sell	2,070 -33,823	-94%	-$58.1K	﹤0.01%	1604
2026 Q1	$60.7K	Buy	35,893 +705	+2%	+$3.09K	0.02%	555
2025 Q4	$182K	Sell	35,188 -26	-0.1%	-$134	0.06%	331
2025 Q3	$184K	Buy	35,214 +1,037	+3%	+$5.41K	0.06%	335
2025 Q2	$131K	Buy	+34,177	New	+$88.4K	0.05%	327

Other funds holding ALDX

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Essential Partners's ALDX Position: Q3 2026 in Review

Essential Partners reduced its Aldeyra Therapeutics (ALDX) stake by 69% in Q3 2026, selling an estimated $2.29K and leaving 633 shares worth $779. The position accounts for ﹤0.01% of the portfolio, ranked #2272.

Essential Partners first reported a position in ALDX in Q2 2025 and has held it in 6 quarters since. The position peaked at $184K in Q3 2025. 5 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.

Essential Partners held 633 shares of Aldeyra Therapeutics worth $779 as of Q3 2026.
Essential Partners sold 1,437 Aldeyra Therapeutics shares in Q3 2026, an estimated $2.29K.
Aldeyra Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2272 holding.
Essential Partners first reported a position in Aldeyra Therapeutics in Q2 2025 and has held it in 6 quarters since.
Essential Partners's Aldeyra Therapeutics position peaked at $184K in Q3 2025.
5 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.